Kaskela Law LLC Announces Shareholder Class Action Lawsuit Against Nano-X Imaging Ltd. (NNOX) and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Kaskela Law LLC announces that a shareholder class action lawsuit has been filed against Nano-X Imaging Ltd.on behalf of investors who purchased Nano-X’s securitiesbetweenAugust 21, 2020andSeptember 15, 2020, inclusive (the “Class Period”).

Investors who purchased Nano-X’s securities during the Class Period and suffered an investment loss in excess of$100,000are encouraged to contact Kaskela Law LLC (D.Seamus Kaskela, Esq.) at (484) 258 – 1585, or by email atskaskela@kaskelalaw.com, to discuss this action and their legal rights and options. Additional information about this action may also be found athttp://kaskelalaw.com/case/nano-x-imaging-ltd/.

As detailed in the complaint, onSeptember 15, 2020, Citron Research (“Citron”) published a report entitled “Nano-X Imaging (NNOX) A Complete Farce on the Market – Theranos 2.0” (the “Citron Report”). The Citron Report summarized Nano-X as “this$3 billioncompany is nothing more than a science project with a simple rendering, minimal R&D, fake customers, no FDA approval, and fraudulent claims that are beyond the realm of possibility.” The Citron Report also alleged that the Company’s claims about its customers with commercial agreements were false, that the Company has not published any data comparing images from its machines with other x-ray machines, and that Nano-X’s statements that it was creating a novel solution to medical imaging was false.

Following this news, shares of Nano-X’s securities fell$12.41per share over two trading days, or over 25% in value, to close at$36.80per share onSeptember 16, 2020, on unusually heavy trading volume.

The complaint alleges that during the Class Period the defendants made a series of false and misleading statements to investors and failed to disclose that: (1) Nano-X’s commercial agreements and its customers were fabricated; (2) Nano-X’s statements regarding its “novel” Nanox System were misleading as the Company never provided data comparing its images with images from competitors’ machines; (3) Nano-X’s submission to the U.S. Food and Drug Administration (“FDA”) admitted the Nanox System was not original; and (4) as a result, defendants’ public statements were materially false and/or misleading at all relevant times.

IMPORTANT DEADLINE: Investors who purchased Nano-X’s securities during the Class Period may,no later thanNovember 16, 2020, seek to be appointed as a lead plaintiff representative in the action. Nano-X investors who suffered an investment loss in excess of$100,000are encouraged to contact Kaskela Law LLC to discuss this opportunity to participate in the action.

Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation. For additional information about Kaskela Law LLC please visitwww.kaskelalaw.com.

CONTACT:
D.Seamus Kaskela, Esq.
KASKELA LAW LLC
18 Campus Boulevard, Suite 100
Newtown Square, PA19073
(484) 258 – 1585
(888) 715 – 1740
www.kaskelalaw.com
skaskela@kaskelalaw.com

See Campaign: http://www.kaskelalaw.com
Contact Information:
D.Seamus Kaskela, Esq.
KASKELA LAW LLC
18 Campus Boulevard, Suite 100
Newtown Square, PA19073
(484) 258 – 1585
(888) 715 – 1740
www.kaskelalaw.com
skaskela@kaskelalaw.com

Tags:
, Wire, Legal Newswire, United States, English

image

Contact Information:

D. Seamus Kaskela, Esq.
KASKELA LAW LLC
18 Campus Boulevard, Suite 100
Newtown Square, PA 19073
(484) 258 – 1585
(888) 715 – 1740
www.kaskelalaw.com
skaskela@kaskelalaw.com

Asiya